Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

June 25, 2013 updated by: Memorial Sloan Kettering Cancer Center

A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to previous chemotherapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Determine the safety and maximum tolerated dose of a single intrahepatic NV1020 injection in patients with hepatic metastases from colon cancer that has failed first-line chemotherapy.
  • Determine the tolerability of this drug in these patients.
  • Determine preliminarily the anti-tumor activity of this drug in these patients.
  • Assess the immunogenicity of NV1020 in these patients.

OUTLINE: This is a dose escalation study.

Patients receive a single intrahepatic arterial injection of NV1020 over 10 minutes with the aid of hepatic arteriography.

Cohorts of 3 patients receive escalating doses of NV1020 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose-limiting toxicity.

Patients are followed at 1, 2, and 3 months post injection. Patients may participate in a separate long term (up to 1 year) follow-up study for continued assessment and monitoring.

PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.

Study Type

Interventional

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10021
        • Memorial Sloan-Kettering Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the colon

    • At least 3 metastatic hepatic lesions involving both lobes
    • No extrahepatic disease
  • Failed first-line combination chemotherapy of fluorouracil plus either leucovorin calcium or irinotecan
  • Herpes simplex virus type-1 seropositive
  • Candidate for intrahepatic arterial infusion pump placement

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC greater than 3,000/mm^3
  • Absolute neutrophil count greater than 1,500/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin greater than 9.0 g/dL
  • No history of any blood clotting disorder (e.g., hemophilia)

Hepatic:

  • Transaminases no greater than 3 times upper limit of normal
  • Bilirubin no greater than 2.0 mg/dL
  • No active hepatitis
  • No history of hepatic fibrosis, cirrhosis, or hemochromatosis

Renal:

  • Creatinine no greater than 2.0 mg/dL

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • All patients must use effective barrier contraception during and for at least 6 months after study
  • HIV negative
  • No active herpes infection
  • No other active uncontrolled infection
  • No prior weight loss of more than 10 lbs within the past month
  • No history of alcohol or other substance abuse
  • No concurrent unstable and/or severe medical or psychological condition
  • No history of any other medical or psychological condition that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 4 weeks since prior immunotherapy (e.g., interleukin-2, interleukin -12, or interferon)
  • No prior gene transfer therapy
  • No prior therapy with cytolytic virus of any type
  • No concurrent immunotherapy during and for 28 days after study therapy
  • No concurrent vaccines during and for 28 days after study therapy

Chemotherapy:

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • No concurrent chemotherapy during and for 28 days after study therapy

Endocrine therapy:

  • No concurrent systemic steroids during and for 28 days after study therapy

Radiotherapy:

  • No prior radiotherapy to the liver
  • No concurrent radiotherapy during and for 28 days after study therapy

Surgery:

  • At least 2 weeks since prior surgery

Other:

  • At least 30 days since prior participation in investigational study
  • No concurrent antiviral agent active against herpes simplex virus (e.g., acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, or cidofovir) during and for 28 days after study therapy
  • No concurrent immunosuppressive agents (e.g., cyclosporine) during and for 28 days after study therapy
  • No other concurrent investigational or anti-cancer agents during and for 28 days after study therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

National Cancer Institute (NCI)

Investigators

  • Study Chair: Yuman Fong, MD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Kemeny N, Jarnagin W, Guilfoyle B, et al.: Results of a phase I, dose-escalating study of the safety, tolerability and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, nv1020, in subjects with hepatic colorectal metastases. [Abstract] Ann Oncol 16 (Suppl 2): A-480, ii283, 2005.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2000

Primary Completion (Actual)

November 1, 2002

Study Completion (Actual)

December 1, 2009

Study Registration Dates

First Submitted

March 3, 2001

First Submitted That Met QC Criteria

June 6, 2003

First Posted (Estimate)

June 9, 2003

Study Record Updates

Last Update Posted (Estimate)

June 26, 2013

Last Update Submitted That Met QC Criteria

June 25, 2013

Last Verified

November 1, 2002

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MSKCC-00022
  • CDR0000068488 (Registry Identifier: PDQ (Physician Data Query))
  • MGENE-NR1-001
  • NCI-G01-1920

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe